Tenofovir disoproxil fumarate (CAS No.: 202138-50-9)

Brief Description
CAS No.: 202138-50-9 Other Names: 9-((R)-2-((Bis(((isopropoxycarbony... MF: C23H34N5O14P
Place of Origin: Jiangxi China (Mainland) Type: Antibiotic and Antimicrobial Agents Grade Standard: Medicine Grade
Usage: Animal Pharmaceuticals Brand Name: Longhao Model Number: LH-003
Purity: 99% Model Number: BP/USP Dosage Form: Powder
Usage: anti-HIV Appearance: almost white crystalline Withdrawal Period: 9 days
Package&Specification: 25kg/drum Storage: Kept in an airtight and dark place Expiry Date: Two years
Molecular formula: C9H14N5O4P Adaptability: Have a preventive effect on 
Delivery Terms & Packaging
Packaging Detail:25kg/drum
Delivery Detail:5-7 days after payment
Specifications
Tenofovir disoproxil fumarate (CAS No.: 202138-50-9)

1. Name: tenofovir disoproxil fumarate
2. CAS No: 147127-20-6
3. MF: C9H14N5O4P
4. Use: anti-HIV
5. Appearance: white

  1. CAS No: 147127-20-6

  2. MF: C23H34N5O14P
  3. Use: anti-HIV
    Appearance: white crystals
    Characteristics: almost white crystalline
    Melting point: 113 to 118°C
    Rotation: -13 to 18°C
    Loss on drying: ≤5.0%
    Contains: ≥99 to 101%
    Molecular weight: 635.51
    CAS registry number: 405165-61-9
    Appearance: white crystalline powder or solid
    Purity: NLT98%
    Specification: enterprise standard
    Molecular structure

 

Product Name

Tenofovir disoproxil fumarate

Synonyms  

9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine fumarate   

  

Molecular Formula  

C19H30N5O10P.C4H4O4

Molecular Weight

635.51

CAS Registry Number

405165-61-9

Appearance

White crystalline powder or solid

Puirty

NLT98%

Specification

Enterprise Standard

  

Molecular Structure 

 

Packing

 

Factory

 

introduction:

Tenofovir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts in controlled studies of tenofovir in treatment-naïve and treatment-experienced adults. There are no study results demonstrating the effect of tenofovir on the clinical progression of HIV. It also has activity against wild-type and lamivudine-resistant HBV.